Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Clinical Pharmacology Study of ME3208 in Healthy Japanese Male Subjects
jRCT2071200077Phase 1Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BJTJ-0045 in chronic graft-versus-host disease (cGVHD) (15 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Safety and tolerability of single or multiple oral doses of ME3208, Pharmacokinetics of ME3208 single and multiple dosing (Part 1) and 1 more. Started Dec 2020; status: completed.
02
Drugs
BJTJ-0045
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on jRCT2071200077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200077.